Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial.
Study Goal
The researchers aimed to determine the effects of a cranberry supplement (not specifically Alanine) on alanine aminotransferase and insulin levels in patients with NAFLD.
Results Summary
The study found that both the cranberry supplement and placebo groups showed significant decreases in alanine aminotransferase and insulin levels after 12 weeks, with both groups following a weight loss diet.
Population
41 patients with non-alcoholic fatty liver disease (NAFLD)
Effective Dosage
Not specified
Duration
12 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
cranberry supplement | decrease | alanine aminotransferase | patients with non-alcoholic fatty liver disease (NAFLD) | - | decreased significantly | #1 |
cranberry supplement | decrease | insulin | patients with non-alcoholic fatty liver disease (NAFLD) | - | decreased significantly | #2 |
weight loss diet | decrease | alanine aminotransferase | patients with non-alcoholic fatty liver disease (NAFLD) | - | decreased significantly | #3 |
weight loss diet | decrease | insulin | patients with non-alcoholic fatty liver disease (NAFLD) | - | decreased significantly | #4 |
A double-blind placebo-controlled randomised clinical trial was conducted on 41 patients with non-alcoholic fatty liver disease (NAFLD). Participants were randomly allocated to receive either a cranberry supplement or a placebo for 12 weeks. Both groups were assigned to follow a weight loss diet. At the end of the study, alanine aminotransferase and insulin decreased significantly in both groups (